Home|Journals|Articles by Year|Audio Abstracts
 

Original Research

BMB. 2021; 6(0): 142-147


Immunohistochemical Analysis of 1,25-dihydroxyvitamin D3 Receptor Expression in Endometrial Cancer Endometrium kanserinde 1,25-dihidroksivitamin D3 Reseptör Ekspresyonunun İmmünohistokimyasal Analizi

Nesibe Kahraman Çetin, Özgür Deniz Turan.




Abstract

Immunohistochemical Analysis of 1,25-dihydroxyvitamin D3 Receptor Expression in Endometrial Cancer
Abstract
Objective: This study aimed to investigate immunohistochemically the expression of 1,25-dihydroxyvitamin-D3-receptors (VDR).in benign and malignant lesions of the endometrial tissue.
Method: The cases were divided into two groups as benign (n = 10) and endometrioid adenocarcinoma (n = 17) according to their endometrial pathology results. The expression of VDR were examined by immunohistochemical method in endometrial tissues of participants (n=27) then, VDR expression levels were compared between groups. The intensity of expression, staining density and overall scores were determined for the semi-quantitative evaluation of VDR expression. Demographic data of the patients were also recorded.
Results: There was no significant difference between the groups in terms of demographic data (p>0.05) except age (p

Key words: Vitamin D, endometrial cancer, vitamin D receptor Anahtar Kelimeler: vitamin D, endometriyal kanser, vitamin D reseptörü






Full-text options


Share this Article


Online Article Submission
• ejmanager.com




ejPort - eJManager.com
Refer & Earn
JournalList
About BiblioMed
License Information
Terms & Conditions
Privacy Policy
Contact Us

The articles in Bibliomed are open access articles licensed under Creative Commons Attribution 4.0 International License (CC BY), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.